Brief: Amneal Announces New Data From Phase 3 Study
07/04/2025 13:48
April 7 (Reuters) - Amneal Pharmaceuticals Inc AMRX.O: AMNEAL ANNOUNCES NEW DATA FROM PHASE 3 STUDY SHOWING SIGNIFICANT IMPROVEMENTS IN SLEEP QUALITY WITH CREXONT® (CARBIDOPA AND LEVODOPA) EXTENDED-RELEASE CAPSULES IN PARKINSON’S DISEASE AMNEAL PHARMACEUTICALS INC - CREXONT IMPROVES PDSS-2 SCORES BY -2.35 Source text: ID:nBw43NLcla Further company coverage: AMRX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Amneal Pharmaceuticals
See all newsFocus: US progesterone supplies tighten as menopause treatment demand grows
U.S. STOCKS ON THE MOVE-Chipotle Mexican Grill, J.B. Hunt, ABM Industries
U.S. STOCKS ON THE MOVE-G-III Apparel, Amneal Pharmaceuticals, BioCardia
U.S. STOCKS ON THE MOVE-Lululemon, Cooper Companies, Cypherpunk Technologies
Amneal Pharma up after Parkinson’s drug shows benefit in late-stage study